用于治疗银屑病的新型选择性TYK2抑制剂氘可来昔替尼(deucravacitinib)  

Deucravacitinib:A Novel Selective TYK2 Inhibitor for the Treatment of Psoriasis

作　　者：余艳平 陈程 范昭泽 苏立林 黄璐 YU Yanping;CHEN Cheng;FAN Zhaoze;SU Lilin;HUANG Lu(Wuhan Jiuzhou Yumin Pharmacutical Technology Co.,Ltd,Wuhan 430071,China;School of Chemical Engineering and Pharmacy,Wuhan Institute of Technology,Wuhan 430205,China;School of Pharmacutical Sciences,Wuhan University,Wuhan 430071,China)

机构地区：[1]武汉九州钰民医药科技有限公司,湖北武汉430071 [2]武汉工程大学化工与制药学院,湖北武汉430205 [3]武汉大学药学院,湖北武汉430071

出　　处：《中国皮肤性病学杂志》2024年第5期585-590,共6页The Chinese Journal of Dermatovenereology

基　　金：武汉东湖国家自主创新示范区2021年度“3551光谷人才计划”项目(武新管人才[2021] 3号)。

摘　　要：氘可来昔替尼(deucravacitinib)是一种新型选择性酪氨酸激酶2(TYK2)抑制剂,已于2022年9月9日经美国FDA批准上市,用于治疗适合全身治疗或光疗的中度至重度斑块型银屑病的成人患者。临床实验表明,氘可来昔替尼具有良好疗效,且安全性较高,患者可耐受。本文对氘可来昔替尼的作用机制、药动学、药效学及最新临床研究进展和不良反应进行综述。Deucravacitinib,a novel selective Tyrosine Kinase 2(TYK2) inhibitor,was approved by the FDA for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy on September 9,2022.Clinical trials have shown that deucravacitinib has good efficacy,high safety,and tolerance.This article reviews the mechanism,pharmacokinetics,pharmacodynamics,and the latest clinical research progress and adverse reactions of deucravacitinib.

关 键 词：银屑病 斑块型银屑病 酪氨酸激酶2抑制剂 氘可来昔替尼 

分 类 号：R986[医药卫生—药品]